Literature DB >> 10334767

Secondary prevention in coronary heart disease. Effects of statins have been in addition to those of aspirin and beta blockers.

J Morrell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10334767      PMCID： PMC1115794          DOI： 10.1136/bmj.318.7195.1419

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  8 in total

1.  Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction.

Authors:  S S Gottlieb; R J McCarter; R A Vogel
Journal:  N Engl J Med       Date:  1998-08-20       Impact factor: 91.245

2.  Secondary prevention in coronary heart disease. Cost effectiveness of treatment must be borne in mind.

Authors:  R E Ferner
Journal:  BMJ       Date:  1998-12-05

3.  Do "America's Best Hospitals" perform better for acute myocardial infarction?

Authors:  J Chen; M J Radford; Y Wang; T A Marciniak; H M Krumholz
Journal:  N Engl J Med       Date:  1999-01-28       Impact factor: 91.245

4.  Secondary prevention in coronary heart disease: baseline survey of provision in general practice.

Authors:  N C Campbell; J Thain; H G Deans; L D Ritchie; J M Rawles
Journal:  BMJ       Date:  1998-05-09

5.  Randomised controlled trial of follow up care in general practice of patients with myocardial infarction and angina: final results of the Southampton heart integrated care project (SHIP). The SHIP Collaborative Group.

Authors:  K Jolly; F Bradley; S Sharp; H Smith; S Thompson; A L Kinmonth; D Mant
Journal:  BMJ       Date:  1999-03-13

6.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

7.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Authors: 
Journal:  Lancet       Date:  1994-11-19       Impact factor: 79.321

8.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Authors: 
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.